Labcorp partnered with ACTO to launch a clinical trial evaluating the impact of multigene panel testing on colorectal cancer patient care and on driving testing among at-risk relatives. Labcorp will provide genetic testing for the study, targeting both clinical decision-making and downstream family cascade screening. The effort addresses ongoing barriers to effective germline and tumor genomic adoption, including which patients get tested and how results influence management. By explicitly including a strategy component for reaching relatives, the trial extends beyond assay performance into real-world implementation. For the genomics industry, the trial is another example of how payers, clinicians, and diagnostics providers are aligning on utility-driven approaches rather than purely testing-volume metrics.